AstraZeneca Enters Strategic Immuno-Oncology Collaboration with Celgene Corporation to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers AstraZeneca and MedImmune announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, a global leader in hematological cancers, for the development and commercialization of MEDI4736 across a range of blood cancers including non-Hodgkin’s lymphoma, myelodysplastic syndromes and multiple myeloma. [AstraZeneca] Press Release AstraZeneca and Innate Pharma Announce Global Co-Development and Commercialization Collaboration for IPH2201 in Immuno-Oncology AstraZeneca and MedImmune announced that they have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA’s proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. [AstraZeneca] Press Release MedImmune and Juno Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration MedImmune and Juno Therapeutics, Inc. announced that they have entered into a new collaboration to conduct combination clinical trials in immuno-oncology with one of Juno’s investigational CD19-directed chimeric antigen receptor T cell candidates and MedImmune’s investigational programmed cell death ligand 1 immune checkpoint inhibitor, MEDI4736. [MedImmune, LLC] Press Release MaxCyte and Johns Hopkins University Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-Cell Therapies MaxCyte® Inc. announced a strategic research collaboration with Johns Hopkins University to develop unique Chimeric Antigen Receptor (CAR) T-cell therapies, which harness patients’ own immune systems to combat cancers. [MaxCyte® Inc.] Press Release Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-Oncology Therapeutics Astellas Pharma Inc. and Potenza Therapeutics, Inc. announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. [Potenza Therapeutics, Inc.] Press Release Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer Merck and Pfizer announced the initiation and first patient treated in the international Phase III study designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab, compared with docetaxel, in patients with stage IIIb/IV non-small cell lung cancer who have experienced disease progression after receiving a prior platinum-containing doublet therapy. [Pfizer Inc.] Press Release Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (Nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending that Opdivo, a PD-1 immune checkpoint inhibitor, be granted approval for use in both first-line and previously treated patients with advanced (unresectable or metastatic) melanoma. [Bristol-Myers Squibb Company] Press Release Celladon Reports Negative Results for CUPID2 Trial of MYDICAR® in Advanced Heart Failure Celladon Corporation announced that its Phase IIb CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR® (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug and device regimen. [Celladon Corporation] Press Release Visabl Website Update Launched Visabl.com, the powerful cloud based antibody and biomarker search engine, announced the largest website update to date. The Visabl.com antibody search function has been completely overhauled, and has the ability to dynamically sort and populate antibodies as you type. [Visabl] Press Release |